Literature DB >> 27788030

PMab-38 Recognizes Canine Podoplanin of Squamous Cell Carcinomas.

Mika K Kaneko1, Ryusuke Honma1,2, Satoshi Ogasawara1, Yuki Fujii1, Takuro Nakamura1, Noriko Saidoh1, Michiaki Takagi2, Yumiko Kagawa3, Satoru Konnai4, Yukinari Kato1.   

Abstract

Podoplanin, a type I transmembrane protein, is expressed in lymphatic endothelial cells. Although we previously developed an anticanine podoplanin monoclonal antibody (mAb), PMab-38, immunohistochemistry (IHC) showed that it did not react with canine lymphatic endothelial cells. Here, we determined whether PMab-38 recognizes canine podoplanin of squamous cell carcinomas (SCCs) and clarified its epitope. In IHC, PMab-38 reacted with 83% of SCCs (15/18 cases). Flow cytometry showed that the epitope of PMab-38 was different from that of the platelet aggregation-stimulating domain of the N-terminus, which was detected by almost all antipodoplanin mAbs such as D2-40 or NZ-1. PMab-38 is expected to be useful for investigating the function of podoplanin in canine tumors.

Entities:  

Keywords:  canine podoplanin; immunohistochemistry; monoclonal antibody

Mesh:

Substances:

Year:  2016        PMID: 27788030     DOI: 10.1089/mab.2016.0036

Source DB:  PubMed          Journal:  Monoclon Antib Immunodiagn Immunother        ISSN: 2167-9436


  8 in total

1.  Podoplanin Expression in Canine Melanoma.

Authors:  Satoshi Ogasawara; Ryusuke Honma; Mika K Kaneko; Yuki Fujii; Yumiko Kagawa; Satoru Konnai; Yukinari Kato
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2016-12-05

2.  The mouse-canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.

Authors:  Yukinari Kato; Tomokazu Ohishi; Manabu Kawada; Naoya Maekawa; Satoru Konnai; Shunsuke Itai; Shinji Yamada; Mika K Kaneko
Journal:  Biochem Biophys Rep       Date:  2018-11-24

3.  PDPN Is Expressed in Various Types of Canine Tumors and Its Silencing Induces Apoptosis and Cell Cycle Arrest in Canine Malignant Melanoma.

Authors:  Masahiro Shinada; Daiki Kato; Satoshi Kamoto; Sho Yoshimoto; Masaya Tsuboi; Ryohei Yoshitake; Shotaro Eto; Namiko Ikeda; Kohei Saeki; Yuko Hashimoto; Yosuke Takahashi; James Chambers; Kazuyuki Uchida; Mika K Kaneko; Naoki Fujita; Ryohei Nishimura; Yukinari Kato; Takayuki Nakagawa
Journal:  Cells       Date:  2020-05-05       Impact factor: 6.600

4.  Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma.

Authors:  Satoshi Kamoto; Masahiro Shinada; Daiki Kato; Sho Yoshimoto; Namiko Ikeda; Masaya Tsuboi; Ryohei Yoshitake; Shotaro Eto; Yuko Hashimoto; Yosuke Takahashi; James Chambers; Kazuyuki Uchida; Mika K Kaneko; Naoki Fujita; Ryohei Nishimura; Yukinari Kato; Takayuki Nakagawa
Journal:  Cells       Date:  2020-11-23       Impact factor: 6.600

Review 5.  Roles of Podoplanin in Malignant Progression of Tumor.

Authors:  Hiroyuki Suzuki; Mika K Kaneko; Yukinari Kato
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

6.  Defucosylated mouse‑dog chimeric anti‑HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors.

Authors:  Hiroyuki Suzuki; Tomokazu Ohishi; Teizo Asano; Tomohiro Tanaka; Masaki Saito; Takuya Mizuno; Takeo Yoshikawa; Manabu Kawada; Mika K Kaneko; Yukinari Kato
Journal:  Oncol Rep       Date:  2022-07-20       Impact factor: 4.136

7.  Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.

Authors:  Yukinari Kato; Takuya Mizuno; Shinji Yamada; Takuro Nakamura; Shunsuke Itai; Miyuki Yanaka; Masato Sano; Mika K Kaneko
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2018-11

8.  Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.

Authors:  Yukinari Kato; Yuji Ito; Tomokazu Ohishi; Manabu Kawada; Takuro Nakamura; Yusuke Sayama; Masato Sano; Teizo Asano; Miyuki Yanaka; Saki Okamoto; Saori Handa; Yu Komatsu; Junko Takei; Mika K Kaneko
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2020-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.